[1]孙晓昕 方纬 张宇辉.99mTc-焦膦酸盐单光子显像：心脏淀粉样变性分型诊断的新应用[J].心血管病学进展,2023,(1):21-24,29.[doi:10.16806/j.cnki.issn.1004-3934.2023.01.006]
　SUN Xiaoxin,FANG Wei,ZHANG Yuhui.99mTc-Pyrophosphate Scintigraphy:New application in Diagnosis and Classification of Cardiac Amyloidosis[J].Advances in Cardiovascular Diseases,2023,(1):21-24,29.[doi:10.16806/j.cnki.issn.1004-3934.2023.01.006]
点击复制

99mTc-焦膦酸盐单光子显像：心脏淀粉样变性分型诊断的新应用()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2023年1期
页码:
21-24,29
栏目:
主题综述
出版日期:
2023-01-25

文章信息/Info

Title:
99mTc-Pyrophosphate Scintigraphy:New application in Diagnosis and Classification of Cardiac Amyloidosis
作者:
孙晓昕1 方纬1 张宇辉2
（北京协和医学院 中国医学科学院阜外医院核医学科,北京 100037;2. 北京协和医学院 中国医学科学院阜外医院心衰中心,北京 100037）
Author(s):
SUN Xiaoxin1; FANG Wei1; ZHANG Yuhui2
(1.Department of Nuclear Medicine,Fuwai Hospital,Peking Union Medical College & Chinese Academy of Medical Sciences,Beijing 100037,China; 2.Heart Failure Center,Fuwai Hospital,Peking Union Medical College & Chinese Academy of Medical Sciences,Beijing 100037,China)
关键词:
心脏淀粉样变性; 99mTc-焦膦酸盐; 单光子; 放射性核素显像
Keywords:
Cardiac amyloidosis; 99mTc-pyrophosphate; Single-photon; Radionuclide imaging
DOI:
10.16806/j.cnki.issn.1004-3934.2023.01.006
摘要:
心脏淀粉样变性临床常见病理类型为免疫球蛋白轻链型和转甲状腺素蛋白相关型。两种不同类型心脏淀粉样变性血清标志物、治疗方法和预后存在很大差异，早期诊断和鉴别心脏淀粉样变性及分型是临床迫切需要的。99mTc-焦膦酸盐是一种骨显像剂，最近的研究显示其在心脏淀粉样变性的分型诊断中起到了重要作用，现对99mTc-焦膦酸盐在心脏淀粉样变性分型诊断中的认识、视觉分级评价和半定量评分标准的建立以及在临床的应用进展进行综述。
Abstract:
The immunoglobulin light chain type and transthyretin related type are the two main clinical pathological types of cardiac amyloidosis(CA). There are great differences in serum markers,treatment methods and prognosis between the two different types of CA. Early diagnosis and differentiation of CA are urgently needed. 99mTc-pyrophosphonate（pyrophosphate？？）(99mTc-PYP) is a bone imaging agent. Recent studies have shown that it plays an important role in the classification of CA. This paper reviews the recognition of 99mTc-PYP in the classification diagnosis of CA,the visual grading evaluation and semi quantitative scoring standards,and the progress of its clinical application

参考文献/References:

[1] Siddiqi OK,Ruberg FL. Cardiac amyloidosis:an update on pathophysiology,diagnosis,and treatment[J]. Trends Cardiovasc Med,2018,28(1):10-21.

[2] Zhao L,Fang Q. Recent advances in the noninvasive strategies of cardiac amyloidosis[J]. Heart Fail Rev,2016,21(6):703-721.

[3] Ruberg FL,Berk JL. Transthyretin(TTR) cardiac amyloidosis[J]. Circulation,2012,126(10):1286-1300.

[4] Ng B,Connors LH,Davidoff R,et al. Senile systemic amyloidosis presenting with heart failure:a comparison with light chain-associated amyloidosis[J]. Arch Intern Med,2005,165(12):1425-1429.

[5] Ando Y. Liver transplantation and new therapeutic approaches for familial amyloidotic polyneuropathy(FAP)[J]. Med Mol Morphol,2005,38(3):142-154.

[6] 田庄,张抒扬,方全. 转甲状腺素蛋白淀粉样变药物治疗研究进展[J]. 国际药学研究杂志,2017,44(2):140-144.

[7] Maurer MS,Schwartz JH,Gundapaneni B,et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy[J]. N Engl J Med,2018,379(11):1007-1016.

[8] 俞子恒,严卉,朱建华. 心肌淀粉样变性的影像学诊断与研究进展[J]. 临床心血管病杂志,2018,34(4):408-412.

[9] Cyrille NB,Goldsmith J,Alvarez J,et al. Prevalence and prognostic significance of low QRS voltage among the three main types of cardiac amyloidosis[J]. Am J Cardiol,2014,114(7):1089-1093.

[10] Liu D,Hu K,St?rk S,et al. Predictive value of assessing diastolic strain rate on survival in cardiac amyloidosis patients with preserved ejection fraction[J]. PLoS One,2014,9(12):e115910.

[11] Liu XH,Shi JY,Zhang DD,et al. Prognostic value of left atrial mechanics in cardiac light-chain amyloidosis with preserved ejection fraction:a cohort study[J]. BMC Cardiovasc Disord,2022,22(1):175.

[12] Barros-Gomes S,Williams B,Nhola LF,et al. Prognosis of light chain amyloidosis with preserved LVEF:added value of 2D speckle-tracking echocardiography to the current prognostic staging system[J]. JACC Cardiovasc Imaging,2017,10(4):398-407.

[13] Hu K,Liu D,Herrmann S,et al. Clinical implication of mitral annular plane systolic excursion for patients with cardiovascular disease[J]. Eur Heart J Cardiovasc Imaging,2013,14(3):205-212.

[14] Matthews SD,Rubin J,Cohen LP,et al. Myocardial contraction fraction:a volumetric measure of myocardial shortening analogous to strain[J]. J Am Coll Cardiol,2018,71(2):255-256.

[15] Tendler A,Helmke S,Teruya S,et al. The myocardial contraction fraction is superior to ejection fraction in predicting survival in patients with AL cardiac amyloidosis[J]. Amyloid,2015,22(1):61-66.

[16] Rubin J,Steidley DE,Carlsson M,et al. Myocardial contraction fraction by M-mode echocardiography is superior to ejection fraction in predicting mortality in transthyretin amyloidosis[J]. J Card Fail,2018,24(8):504-511.

[17] Fontana M,Pica S,Reant P,et al. Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis[J]. Circulation,2015,132(16):1570-1579.

[18] Bokhari S,Morgenstern R,Weinberg R,et al. Standardization of 99mTechnetium pyrophosphate imaging methodology to diagnose TTR cardiac amyloidosis[J]. J Nucl Cardiol,2018,25(1):181-190.

[19] Bokhari S,Casta?o A,Pozniakoff T,et al. (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses[J]. Circ Cardiovasc Imaging,2013,6(2):195-201.

[20] Treglia G,Glaudemans A,Bertagna F,et al. Diagnostic accuracy of bone scintigraphy in the assessment of cardiac transthyretin-related amyloidosis:a bivariate meta-analysis[J]. Eur J Nucl Med Mol Imaging,2018,45(11):1945-1955.

[21] Quarta CC,Gonzalez-Lopez E,Gilbertson JA,et al. Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis[J]. Eur Heart J,2017,38(24):1905-1908.

[22] Hasegawa K,Uzui H,Fukuoka Y,et al. Abdominal fat pad fine-needle aspiration for diagnosis of cardiac amyloidosis in patients with non-ischemic cardiomyopathy[J]. Int Heart J,2022,63(1):49-55.

[23] Katzmann JA,Abraham RS,Dispenzieri A,et al. Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice[J]. Clin Chem,2005,51(5):878-881.

[24] Gillmore JD,Maurer MS,Falk RH,et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis[J]. Circulation,2016,133(24):2404-2412.

[25] Phull P,Sanchorawala V,Connors LH,et al. Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis(ATTR)[J]. Amyloid,2018,25(1):62-67.

[26] 何山,田庄,任超,等. 转甲状腺素蛋白淀粉样变心肌病的规范化诊断[J]. 中国实用内科杂志,2020,40(12):978-980.

[27] 中华医学会心血管病学分会心力衰竭学组,中华心血管病杂志编辑委员会. 转甲状腺素蛋白心脏淀粉样变诊断与治疗中国专家共识[J]. 中华心血管病杂志,2021,49(4):324-332.

[28] Perugini E,Guidalotti PL,Salvi F,et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy[J]. J Am Coll Cardiol,2005,46(6):1076-1084.

[29] 任静芸,任超,杜延荣,等. 99Tc m-焦膦酸盐显像在转甲状腺素心肌淀粉样变中的应用[J]. 中华核医学与分子影像杂志,2020,40(10):577-582.

[30] 任超,任静芸,杜延荣,等. 99Tc m-PYP延迟及断层显像诊断转甲状腺素蛋白相关心脏淀粉样变的应用价值[J]. 中华核医学与分子影像杂志,2022,42(1):1-6.

[31] Poterucha TJ,Elias P,Bokhari S,et al. Diagnosing transthyretin cardiac amyloidosis by technetium Tc 99m pyrophosphate:a test in evolution[J]. JACC Cardiovasc Imaging,2021,14(6):1221-1231.

[32] Hanna M,Ruberg FL,Maurer MS,et al. Cardiac scintigraphy with technetium-99m-labeled bone-seeking tracers for suspected amyloidosis:JACC review topic of the week[J]. J Am Coll Cardiol,2020,75(22):2851-2862.

[33] Zhu Y,Pan R,Peng D,et al. Pitfalls of the semi-quantitative analyzing (99m)Tc-pyrophosphate planar images for diagnosing transthyretin cardiac amyloidosis:a possible solution[J]. Diagnostics (Basel),2022,12(1):94.

[34] 中华医学会核医学分会心脏学组,国家核医学专业质控中心. 99Tc m-焦膦酸盐单光子显像诊断转甲状腺素蛋白相关心脏淀粉样变的技术操作规范[J]. 中华核医学与分子影像杂志,2022,42(3):165-171.

[35] Ren C,Ren J,Tian Z,et al. Assessment of cardiac amyloidosis with 99mTc-pyrophosphate(PYP) quantitative SPECT[J]. EJNMMI Phys,2021,8(1):3.

[36] Avalon JC,Fuqua J,Deskins S,et al. Quantitative single photon emission computed tomography derived standardized uptake values on 99mTc-PYP scan in patients with suspected ATTR cardiac amyloidosis[J]. J Nucl Cardiol,2022.doi:10.1007/s12350-022-02988-5. Online ahead of print.

相似文献/References:

[1]张焰,饶莉.心脏淀粉样变性诊疗进展[J].心血管病学进展,2015,(5):527.[doi:10.3969/j.issn.1004-3934.2015.05.001]
　ZHANG Yan,RAO Li.Advances in Diagnosis and Treatment of Cardiac Amyloidosis[J].Advances in Cardiovascular Diseases,2015,(1):527.[doi:10.3969/j.issn.1004-3934.2015.05.001]
[2]杜明亮 郑晓群.心脏淀粉样变性临床研究进展[J].心血管病学进展,2022,(7):636.[doi:【DOI】10.16806/j.cnki.issn.1004-3934.2022.07.000]
[3]侯为洁 龚艳君.心脏磁共振在心脏淀粉样变性中的应用进展[J].心血管病学进展,2023,(9):796.[doi:10.16806/j.cnki.issn.1004-3934.2023.09.007]
　HOU Weijie,GONG Yanjun.Application of Cardiac Magnetic Resonance in Cardiac Amyloidosis[J].Advances in Cardiovascular Diseases,2023,(1):796.[doi:10.16806/j.cnki.issn.1004-3934.2023.09.007]

更新日期/Last Update: 2023-03-10